SHERMAN JEFFREY W 4

What Happened

• Jeffrey W. Sherman, a director of Larimar Therapeutics, purchased 5,000 shares of common stock on February 27, 2026 at $5.00 per share for a total cash outlay of $25,000. The transaction is reported as a purchase (code P) in an underwritten offering.

Key Details

• Transaction date and price: 2026-02-27, 5,000 shares at $5.00 per share.
• Total value: $25,000.
• Filing date / report period: Form 4 filed 2026-03-02 for the 2026-02-27 transaction (no late-file notation in the provided record).
• Footnote: Shares were purchased in Larimar’s underwritten offering, which closed on February 27, 2026.
• Shares owned after transaction: Not specified in the supplied summary of the filing.

Context

• This was a straight purchase of company stock in the offering (a bullish signal in the sense the insider bought shares), but the amount ($25k) is relatively modest. For retail investors, purchases by directors can indicate confidence, but one small purchase should be weighed with other insider activity and company fundamentals.